Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 7/20 | 0.81 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21321511 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLAKDM4EMAPT | |
| SCHEMBL19209754 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLAKDM4EMAPT | |
| SCHEMBL11936653 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLAKDM4EMAPT | |
| SCHEMBL12145776 | 0.90 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18161468 | 0.90 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL1377049 | 0.90 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102890 | 0.90 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102870 | 0.90 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19259307 | 0.89 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18636844 | 0.89 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180338910-A1 | INTRANASAL ADMINISTRATION OF GLUTAMATE CARBOXYPEPTIDASE (GCP-II) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-11-29 | — | — | US | claimed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4648799-A1 | LIGAND-DRUG CONJUGATES | Sun Pharma Advanced Research Company Ltd (IN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2025-04-03 | — | — | US | disclosed |
| US-12252534-B2 | Humanized anti-CD3 antibodies, conjugates and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3838298-B1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-3777898-B1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12178892-B2 | Compounds for positron emission tomography | PURDUE RESEARCH FOUNDATION (US) | 2024-12-31 | — | — | US | disclosed |
| US-20140073763-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130011362-A1 | TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS | PHASERX, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | GEORGETOWN UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2187965-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010045598-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009026177-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011362-A1 | TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS | FOLR1, FOLR2, DHFR | FOLH1 14/4885NAALAD2 3927/4885RIMKLA 675/4885 |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 32/4885RIMKLA 801/4885 |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20180338910-A1 | INTRANASAL ADMINISTRATION OF GLUTAMATE CARBOXYPEPTIDASE (GCP-II) INHIBITORS | ENPEP, DNPEP, FOLH1 | FOLH1 3/4885NAALAD2 29/4885RIMKLA 121/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885NAALAD2 208/4885RIMKLA 1263/4885 |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | FOLH1 157/4885NAALAD2 659/4885RIMKLA 874/4885 |
| US-12178892-B2 | Compounds for positron emission tomography | FOLH1, FOLR2, FOLR1 | FOLH1 1/4885NAALAD2 67/4885RIMKLA 110/4885 |
| US-12252534-B2 | Humanized anti-CD3 antibodies, conjugates and uses thereof | CD2, CD47, KLK3 | FOLH1 43/4885NAALAD2 172/4885RIMKLA 2261/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20140073763-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885NAALAD2 49/4885RIMKLA 513/4885 |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885NAALAD2 3/4885RIMKLA 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.